Loading...
XJPX
4595
Market cap200mUSD
Dec 05, Last price  
1,638.00JPY
1D
-1.09%
1Q
2.50%
Jan 2017
185.74%
IPO
164.19%
Name

Mizuho Medy Co Ltd

Chart & Performance

D1W1MN
XJPX:4595 chart
P/E
8.27
P/S
2.73
EPS
198.07
Div Yield, %
7.33%
Shrs. gr., 5y
14.87%
Rev. gr., 5y
12.20%
Revenues
11.43b
+4.00%
3,248,000,0003,997,355,0004,083,053,0004,962,189,0005,623,976,0006,425,082,0006,426,910,0004,203,303,00012,886,270,00017,581,830,00010,989,735,00011,429,000,000
Net income
3.77b
-0.03%
139,000,000317,297,000257,601,000395,205,000660,049,000919,205,000874,344,000306,346,0004,816,772,0007,838,094,0003,774,239,0003,773,000,000
CFO
3.35b
-16.13%
0215,830,00017,712,000187,282,000877,678,000670,668,000745,001,000295,417,0005,596,506,0006,172,506,0003,991,831,0003,348,000,000
Dividend
Dec 29, 202545 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan. The company provides immunoassay test products, such as influenza virus kits; RS virus and human metapneumovirus antigen test kits; streptococcus pneumoniae antigen and legionella antigen test kits; mycoplasma pneumoniae antigen test kits; adenovirus antigen test kits; rotavirus and adenovirus antigen test kits; norovirus antigen test kits; group a streptococcal antigen test kits; pregnancy test kits; ovulation test kits; and fecal occult blood test kits. It also offers gene analysis instrument; SARS-CoV-2 detection kits; and mycoplasma pneumoniae nucleic acid kits. In addition, the company engages in import and export activities. It also operates in the United States, Belgium, Finland, Netherlands, Taiwan, Thailand, etc. The company was incorporated in 1977 and is headquartered in Tosu, Japan.
IPO date
Dec 17, 2015
Employees
175
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT